T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia

Gain-of-function mutations of FLT3 (FLT3-ITD), comprises up to 30% of normal karyotype acute myeloid leukemia (AML) and is associated with an adverse prognosis. Current FLT3 kinase inhibitors have been tested extensively, but have not yet resulted in a survival benefit and novel therapies are awaite...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Alachkar, Houda, Mutonga, Martin, Malnassy, Gregory, Park, Jae-Hyun, Fulton, Noreen, Woods, Alex, Meng, Liping, Kline, Justin, Raca, Gordana, Odenike, Olatoyosi, Takamatsu, Naofumi, Miyamoto, Takashi, Matsuo, Yo, Stock, Wendy, Nakamura, Yusuke
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2015
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741775/
https://ncbi.nlm.nih.gov/pubmed/26450903
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi